Regulatory harmonization, expanding site networks, and new consortium models are changing the calculus. Pharmaceutical and biopharmaceutical sponsors evaluating multi-regional expansion now have more infrastructure to work with than most realize.
This article breaks down where the opportunities sit, what regulatory readiness actually means market by market, and how sponsors can build site networks without starting from zero.
Key Takeaways
- Non-communicable disease trials remain scarce across Africa despite rising need and existing site capacity.
- WHO maturity levels, AMA, and AVAREF are cutting regulatory approval timelines in higher-readiness countries.
- Site networks outside South Africa report strong consent (80%+) and retention (85-96%) rates.
- Declining donor funding is opening capacity for sponsor-funded trials across established African site networks.
- An experienced CRO partner can compress African site identification and start-up timelines.
Why Africa Is Emerging as a Clinical Research Destination
Africa's disease profile is shifting. Infectious disease still dominates research budgets, but cardiovascular disease, diabetes, and cancer are climbing fast on the continent's health agenda. Trial activity hasn't caught up.
The genetic diversity case is strong. African populations represented just 1.1% of GWAS data by 2021, down from 3% in 2019, according to a 2024 peer-reviewed genomics review. Sequencing 426 individuals across 50 ethnolinguistic groups uncovered more than 3 million previously unidentified genetic variants.
For oncology and precision medicine programs, that is an untapped biomarker landscape and a scientific argument for broader trial representation, not just an ethical one.
The Concentration Problem
Trial activity that does happen in Africa clusters heavily in a handful of countries. A 2023 DIA analysis of ClinicalTrials.gov found:
- Africa accounted for just 3.58% of all registered global studies (15,717 of 438,902)
- South Africa and Egypt together made up roughly 73% of those African records
- The remaining 53 countries shared just over 4,100 studies combined
That imbalance isn't a capacity problem so much as a visibility problem. Site networks report solid operational performance where sponsors have actually looked.
A 2025 Applied Clinical Trials report on sub-Saharan network data found consent rates above 80% and retention between 85% and 96%. Those figures challenge the assumption that operational risk is higher outside established hubs.
Underserved Therapeutic Areas Ripe for Expansion
Oncology, cardiovascular disease, and sickle cell disease all show heavy underrepresentation despite existing site infrastructure:
- Only 26 of 736 registered African trials were cancer-related interventional studies; just 6 ran in predominantly Black-patient countries
- South Africa was the only sub-Saharan country in major heart-failure and ACS RCTs (14.2% and 8.2% of studies)
- Sickle cell trial sites grew from 0.5% to 13.5% of global enrollment centers between 1990 and 2024, per IQVIA
The arpraziquantel program offers a workable blueprint. EDCTP and GHIT co-funded the pivotal Phase III trial across Cote d'Ivoire and Kenya, achieving cure rates above 90%. The EMA issued a positive opinion in December 2023. Consortium funding plus multi-country site coordination moved a neglected-disease therapy through pivotal trials and to regulatory review.
Regulatory Readiness Across African Markets
WHO's Global Benchmarking Tool classifies national regulatory authorities on a four-tier maturity scale:
| Maturity Level | What It Signals |
|---|---|
| ML1 | Some regulatory elements exist |
| ML2 | Evolving system, partial functionality |
| ML3 | Stable, well-functioning, integrated system |
| ML4 | Advanced performance with continuous improvement |
ML3/ML4 status tells sponsors a country's regulator can reliably process applications, run inspections, and coordinate with international standards. Ethiopia reached ML3 in 2025, joining Senegal, Rwanda, and Zimbabwe, which achieved ML3 status in 2024.
Two frameworks are reshaping multi-country approval logistics:
- African Medicines Agency (AMA) : an African Union specialized agency built to strengthen member states' capacity to regulate medical products at scale
- African Medicines Regulatory Harmonization (AMRH) : active since 2009 across 5 regional economic communities and 55 national regulatory authorities, targeting weak legislation and slow registration timelines
The African Vaccine Regulatory Forum (AVAREF) enables joint or assisted ethics and regulatory reviews across multiple countries at once. Documented examples include a Merck/NewLink Phase III assisted review completed in Guinea in two weeks, and a GSK Phase II joint review spanning Ghana, Nigeria, Cameroon, Mali, and Senegal in three months.
What This Means for Study Timelines
Regulatory readiness affects three planning factors for sponsors:
- Documentation requirements vary by ML tier : higher-maturity regulators expect more rigorous dossiers but process them faster
- Ethics committee coordination becomes far simpler under AVAREF's joint-review model versus sequential country-by-country submission
- Approval timelines compress meaningfully in ML3/ML4 markets, though variability between countries remains significant
Ghana has positioned itself as a Regional Centre of Regulatory Excellence, and its Food and Drugs Authority has completed structured evaluation to strengthen review capacity. Sponsors evaluating multi-country African protocols should map regulatory maturity before finalizing country selection.
Building Site Networks: Capacity and Partnerships
Sponsors don't have to build African site networks from scratch. Several platforms already catalog trial-ready capacity:
- Clinical Trials Community (CTC Africa) — a registry reporting roughly 3,800 known sites across 54 countries
- BIO Ventures for Global Health's African Consortium for Cancer Clinical Trials (AC3T) — profiles 62 oncology-capable sites across 21 sub-Saharan countries
- Africa Clinical Research Network — describes itself as the first African-led network connecting researchers and site capabilities across therapeutic areas
- EDCTP — co-funds multicountry trials and links them to implementation infrastructure, as demonstrated in the arpraziquantel program
These are not full Phase II–IV capability censuses, but they are a solid starting point for feasibility work.
Infrastructure Gaps That Still Matter
Several constraints still show up at many sites:
- Limited electronic health record adoption
- Continued reliance on manual data entry
- Under-resourced regulators
- Slower approval cycles in lower-maturity markets
These gaps are manageable with the right site-management approach, but they need to be planned for—not discovered mid-trial.
Why Local Partnership Models Matter
A CRO with established regional relationships identifies feasible sites faster than a sponsor entering unassisted. Site selection drives a large share of trial delays industry-wide, and that risk compounds where sponsors lack investigator relationships.
DRK Research Solutions pairs site identification and feasibility work with a Regional Head dedicated to Africa and the USA. Local relationship-building plus global regulatory know-how shortens the path from protocol design to first patient enrolled.
Challenges and Risk Mitigation Strategies
Donor funding is contracting. Roughly 90% of sub-Saharan African clinical trials rely on external funding, according to a 2026 systematic review in PLOS Global Public Health. Broader research funding across the region fell an estimated 18% between 2022 and 2024, with East Africa hit hardest. That decline threatens infrastructure built on donor cycles. It also opens a lane for sponsor-funded trials to sustain capacity that would otherwise erode.
Ethics and participant costs raise parallel risks. South Africa's health products regulator requires sponsors to plan post-trial access so participants can obtain investigational products after a study ends. Reimbursement research from South Africa found real costs matter: one site paid roughly $10 plus a meal per visit, while researchers recommended closer to $20 given the transport costs participants reported.
Budget models deserve the same scrutiny. Legacy cost assumptions based on outdated regional benchmarks can undervalue site performance and slow enrollment. Tufts CSDD estimates a single day of trial delay costs roughly $800,000 in unrealized drug sales industry-wide, plus $40,000 in direct daily trial costs.
Practical mitigations include:
- Shifting capacity toward sponsor-funded trials as donor cycles contract
- Building post-trial access plans into protocols from the start
- Setting participant reimbursement to actual local costs, not token amounts
- Paying fair market value based on site output rather than legacy benchmarks
How DRK Research Solutions Supports Sponsors Entering African Markets
DRK's Regional Head for USA & Africa, Dr. Onesmo Mpanju, anchors the company's approach to bridging sponsor needs with African research institutions. From DRK's Aldie, Virginia base, he pairs regional relationship management with cross-market coordination across these two connected regions.
DRK's CRO capabilities span the full trial lifecycle:
- Site identification and feasibility assessment
- Regulatory strategy and submissions across GxP standards including ICH-GCP, US FDA, MHRA, EU GMP, and WHO PQ
- Phase II-IV clinical operations and project management
- Clinical data management, biostatistics, and post-authorization studies
DRK operates across Europe, the Middle East, Asia, Africa, and the Americas. Sponsors get a single partner for multi-regional coordination instead of juggling separate vendors per continent.
That network, paired with localized market knowledge, helps sponsors navigate site selection and regulatory submissions in markets where in-house teams often lack established relationships.
Frequently Asked Questions
Which country is best for clinical research?
It depends on therapeutic area and regulatory maturity. South Africa offers established infrastructure and high WHO maturity level (ML) status, while Ghana has earned regulatory excellence recognition—match the country to your indication and timeline.
Do you get paid for clinical trials in South Africa?
Participants are typically reimbursed for time and travel under ethics-approved protocols; amounts vary by study. Under ethical trial design, payment is not meant to be the primary enrollment incentive.
What makes a country "regulatory ready" for clinical trials?
Readiness is measured mainly through WHO's maturity level framework (ML1–ML4). Harmonization initiatives such as AMA and AVAREF add joint reviews that streamline multi-country coordination.
How long does it typically take to get regulatory approval for a trial in Africa?
Timelines vary widely by country and maturity level. Harmonized joint reviews under AVAREF have compressed approval to as little as two weeks to three months in documented cases.
What diseases are most researched in African clinical trials today?
HIV/AIDS, tuberculosis, and malaria have historically dominated African clinical research. Oncology and cardiovascular disease represent significant, underexplored growth opportunities.
How can sponsors identify trial-ready sites in Africa?
Platforms like BIO Ventures for Global Health and Clinical Trials Community catalog site capacity across the continent. Partnering with an experienced CRO adds vetting, feasibility assessment, and ongoing site management.
